5-HT1A receptor-dependent modulation of emotional and neurogenic deficits elicited by prolonged consumption of alcohol

Arnauld Belmer1,2, Omkar L. Patkar1,2, Vanessa Lanoue3 & Selena E. Bartlett1,2

Repeated episodes of binge-like alcohol consumption produce anxiety, depression and various deleterious effects including alterations in neurogenesis. While the involvement of the serotonin receptor 1A (5-HT1A) in the regulation of anxiety-like behavior and neurogenesis is well documented, its contribution to alcohol withdrawal-induced anxiety and alcohol-induced deficits in neurogenesis is less documented. Using the Drinking-In-the-Dark (DID) paradigm to model chronic long-term (12 weeks) binge-like voluntary alcohol consumption in mice, we show that the selective partial activation of 5-HT1A receptors by tandospirone (3 mg/kg) prevents alcohol withdrawal-induced anxiety in a battery of behavioral tests (marble burying, elevated-plus-maze, open-field), which is accompanied by a robust decrease in binge-like ethanol intake (1 and 3 mg/kg). Furthermore, using triple immunolabelling of proliferation and neuronal differentiation markers, we show that long-term DID elicits profound deficits in neurogenesis and neuronal fate specification in the dorsal hippocampus that are entirely reversed by a 2-week chronic treatment with the 5-HT1A partial agonist tandospirone (3 mg/kg/day). Together, our results confirm previous observations that 5-HT1A receptors play a pivotal role in alcohol drinking behavior and the associated emotional and neurogenic impairments, and suggest that 5-HT1A partial agonists represent a promising treatment strategy for alcohol abuse.

Alcoholism is regarded as a chronic relapsing disorder, with the development of alcohol addiction a progressive cycle involving extended periods of heavy alcohol use, with repeated episodes of binge-like consumption and abstinence. In society, alcohol abuse is highly prevalent with significantly higher rates of co-occurrence with emotional and mood disorders including anxiety and depression. In turn, increased anxiety levels following alcohol withdrawal are key factors contributing to craving and relapse. Animal studies using non-contingent/forced alcohol delivery (e.g., vapor inhalation, injection, gavage) or contingent models based on continuous access to alcohol (2-bottle choice) have also revealed that withdrawal from chronic alcohol exposure increases stress responsiveness and depression-like behaviors, and alters hippocampal neurogenesis. However, no study to date has investigated the consequences of prolonged periods (12 weeks) of voluntary binge-like alcohol consumption and abstinence on anxiety-like behaviors and hippocampal neuron proliferation or differentiation.

The “Drinking-In-the-Dark” (DID) paradigm is a model of voluntary binge-like alcohol drinking, in which animals have a daily 2-hour limited access to ethanol followed by a 24-hour abstinence period. Using this procedure, the high-drinking C57Bl/6J mouse strain consumes pharmacologically relevant levels of ethanol (blood ethanol concentration ≥1.0 g/L) and shows signs of behavioral intoxication. In adult mice chronically exposed for short term periods (6 weeks), this procedure was shown to elicit increased anxiety- and depression-like behaviors as early as 24 hours after the last drinking session and up to 21 days into protracted withdrawal.

The serotonin (5-hydroxytryptamine, 5-HT) system has been widely implicated in the regulation of emotion, impulsivity, mood, reward and arousal. As such, dysregulation of serotonin homeostasis is distinctly involved in the development of anxiety- and depression-related disorders. In line with this, profound functional changes in
5-HT signaling have been observed in the limbic system following acute and chronic alcohol exposure. Selective serotonin reuptake inhibitor (SSRI) antidepressants elevate 5-HT availability and promote hippocampal neurogenesis, which is required for antidepressant effects, a positive relationship between 5-HT signaling and hippocampal neurogenesis has been established, with the role of the 5-HT1A receptor becoming well elucidated in both anxiety/depression and neurogenesis.

Chronic alcohol exposure downregulates 5-HT1A receptor expression in the hippocampus but upregulates 5-HT1A receptor expression and function in the raphé. Interestingly, 5-HT1A receptor activation by the non-selective partial agonists buspirone was shown to reduce alcohol drinking and alcohol withdrawal-induced anxiety in rodents. These particular studies, however, used a protocol in which animals are forced to consume alcohol by including ethanol in a liquid diet as the sole source of nutrient, making their motivation to drink ethanol in relation to emotional deficits questionable. Additionally, it is now well accepted that buspirone is not selective for 5-HT1A receptors but also displays an antagonist activity at dopamine D2-like receptors. Indeed, the effect of buspirone on alcohol drinking as well as some anxiety-related behaviors are mediated by D2-like receptor blockade. Furthermore, we and others have demonstrated that buspirone has a complex action with both anxiolytic and anxiogenic, or motor effects in rodents, which could explain the inconsistent results on the benefit of buspirone reported in human alcoholics.

Together, these data suggest that further work is needed to clarify the specific contribution of 5-HT1A receptors in both alcohol drinking behavior and alcohol-withdrawal induced anxiety.

Tandospirone is a 5-HT1A partial agonist that, unlike buspirone, presents a high selectivity of two to three orders of magnitude over dopamine, adrenergic and other 5-HT receptors. Tandospirone is an effective anxiolytic drug marketed as Sediel in China and Japan, that is well tolerated and presents limited adverse effects and low abuse liability. Animal studies have also demonstrated that chronic tandospirone treatment improves hippocampal neurogenesis and inhibits stress-induced anxiety and neurogenic deficits. However, the ability of tandospirone to reduce anxiety-like behavior and neurogenic deficits following long-term binge-like alcohol consumption has not been described. To address this question, we used the long-term DID (12 to 15 weeks) model to investigate the effect of tandospirone on (1) alcohol withdrawal-induced anxiety in a battery of behavioral tests (marble burying, elevated-plus-maze and open-field), (2) the maintenance of alcohol binge-like drinking and (3) alcohol-induced deficits in hippocampal neurogenesis. Here, we report for the first time that the selective partial activation of 5-HT1A receptors by tandospirone reverses alcohol withdrawal-induced anxiety-like behaviors following 12 weeks of exposure, which is accompanied by a robust decrease in alcohol binge-like consumption. In addition, we show that a 2-week tandospirone treatment is sufficient to totally reverse the impairments in hippocampal neurogenesis and neuronal fate specification caused by 15 weeks of binge-like alcohol consumption. Taken together, our results complement previous studies by demonstrating the integral role of 5-HT1A receptors in emotion-driven alcohol binge-like drinking behavior and neurogenic impairments elicited by prolonged binge-like consumption of alcohol.

Results

Partial activation of 5-HT1A receptors by tandospirone reverses anxiety-like behavior elicited by withdrawal from 12 weeks of binge-like alcohol consumption in the DID. To evaluate the contribution of 5-HT1A receptors in anxiety-like behavior following withdrawal from long-term binge-like drinking, we investigated the effects of the 5-HT1A partial agonist tandospirone (3 mg/kg) on mice experiencing a 24-h withdrawal from alcohol in a battery of behavioral tests (marble burying, elevated-plus-maze and open-field) (Fig. 1A). In the marble burying test, we observed a significant increase in anxiety-related marble digging behavior in alcohol-withdrawn mice compared to naive mice, and this increase was prevented by tandospirone pre-treatment (Fig. 1B). A representative image of the marble buried for the three groups is shown (Fig. 1C). In the elevated-plus-maze test, the number of entries and the percent of time spent in the open-arm were significantly reduced in ethanol-withdrawn animals compared to naive animals, and this anxiety-related avoidance of heights/open space was abolished by tandospirone pre-treatment (Fig. 1D,E). Since the total number of entries was not different between naive, alcohol withdrawn and tandospirone-treated alcohol withdrawn mice (Fig. 1F), the open arm entries expressed as the percentage of the total entries was also significantly reduced in vehicle-treated alcohol-withdrawn mice compared to naive mice, with tandospirone treatment also preventing this reduction (Fig. 1G). It demonstrates that the anti-anxiety effect of tandospirone following alcohol withdrawal is not mediated by alterations in locomotor activity. A representative image of the ambulatory behavior in the elevated-plus-maze is shown for the three groups (Fig. 1H). Similarly, in the open-field test, the distance travelled in the center was reduced in alcohol-withdrawn mice compared to naive animals, and this reduction was absent in tandospirone treated animals (Fig. 1I). The total distance travelled was not significantly different between groups (Figure S1A) and therefore, the distance travelled in the center expressed in percentage of the total distance travelled was significantly reduced in vehicle-treated alcohol withdrawn mice but not in tandospirone-treated alcohol withdrawn mice (Fig. 1J). Again, it reveals that the anxiolytic effect of tandospirone is not mediated by alterations in locomotor activity. Taken together, these results demonstrate that the anxiogenic effects of alcohol-withdrawal after 12 weeks of binge-like consumption in the DID are totally reversed by the selective partial activation of 5-HT1A receptors by tandospirone.

Partial activation of 5-HT1A receptors by tandospirone reduces binge-like alcohol consumption in long-term ethanol consuming mice in the DID. We assessed whether the anti-anxiety effect of partial activation of 5-HT1A receptors during daily withdrawal in the DID could affect the levels of alcohol intake. We tested the effect of tandospirone pre-treatment on the levels of binge-like alcohol intake (Fig. 2A). Compared to vehicle, tandospirone significantly reduced alcohol intake at 30-min (Fig. 2B), and 2 h (Fig. 2C). To evaluate the contribution of any non-specific effects in the efficacy of tandospirone to reduce alcohol consumption, we...
Figure 1. Tandospirone prevents withdrawal-induced anxiety following long-term chronic binge-like alcohol consumption. (A) Experimental design of anxiety-like behavioral testing in the marble burying (B–C), elevated-plus-maze (D–H) and the open-field (I–J) following 12 weeks of binge-like alcohol consumption in the drinking-in-the-dark (DID). Alcohol-naive animals were treated with vehicle (Naive + veh) and alcohol-withdrawn animals with either vehicle (AW + Veh) or Tandospirone (AW + Tando). (B) Marble burying test showing an increased number of marble buried by alcohol-withdrawn mice that is prevented by tandospirone pretreatment. (C) Representative photograph of marble burying behavior for the different groups. (D–E) Alcohol-withdrawal reduces the number of entries (D) and the percentage of time spent (open arm/ open arm + closed arm, E) in the open arm of the elevated plus maze in vehicle- but not tandospirone-pretreated mice, as compared to naïve mice treated with vehicle. (F) The total number of entries in the different arms of the elevated-plus-maze is not altered by either alcohol-withdrawal or tandospirone pretreatment. (G) The number of open-arm entries expressed as a percentage of total entries (open arm/open arm + closed arm) is reduced in
alcohol-withdrawn mice, which is prevented by tandospirone pretreatment, as compared to naive mice treated with vehicle. (H) Representative picture of the exploratory behaviour for the different groups. (I–J) Alcohol-withdrawal reduces the distance travelled in the center of the open-field (I) and the distance in the center as a percentage of the total distance in the open-field (J) in vehicle- but not tandospirone-pretreated mice, as compared to naive mice treated with vehicle. Data are presented as mean ± S.E.M.; n = 5 mice/group. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; NS: non-significant (One-way ANOVA followed by Bonferroni post-hoc analysis).

Further tested the effect of tandospirone on sucrose intake, general locomotor activity and alcohol metabolism. We did not observe any alterations to the consumption of sucrose at 30 min (or 2h, Figure S1b) with any dose of tandospirone administered (0, 0.3, 1 and 3 mg/kg) (Fig. 2D). Additionally, while a slight reduction in locomotor activity was observed at 10 and 15 minutes after tandospirone injection, ambulatory behavior was not significantly altered by tandospirone after 30 min post-injection, i.e. during the period corresponding to the testing of alcohol/sucrose intake or anxiety (Fig. 2E). Finally, assessing tandospirone non-specificity on alcohol metabolism revealed no effect on the latency (Fig. 2F) and duration (Fig. 2G) of the loss-of-righting reflex, as compared to vehicle. Together, these results demonstrate that tandospirone specifically reduces the maintenance of binge-like alcohol drinking behaviors following long-term exposure in the DID.

**Chronic activation of 5-HT$_{1A}$ receptors reverses the neurogenic deficits induced by long-term binge-like alcohol consumption in the DID.** Since chronic treatment with tandospirone was previously shown to increase hippocampal neurogenesis and prevent stress-induced deficits in neurogenesis in rats$^{34,35}$, we investigated the effect of a 2-week chronic treatment (3 mg/kg/day) on the incorporation of BrdU, the expression of the proliferation marker, Ki67 and the marker of immature neurons, doublecortin (DCX) in the dentate gyrus of mice long-term exposed to alcohol-binge-like consumption in the DID (Fig. 3A). We observed that prolonged binge-like alcohol consumption significantly reduced the density of BrdU immunoreactive (BrdU$^+$) cells in the dentate gyrus of alcohol-withdrawn mice compared to naive mice, and this reduction was prevented by chronic tandospirone treatment (Fig. 3B). Quantification of Ki67$^+$ immunoreactive (Ki67$^+$) cells revealed no effect of alcohol exposure or tandospirone treatment on the density of proliferating cells compared to vehicle-treated naive animals (Fig. 3C). However, long-term alcohol exposure significantly reduced the density of DCX immunoreactive (DCX$^+$) immature neurons compared to naive animals, and chronic tandospirone treatment significantly reverses this reduction (Fig. 3D). Representative micrographs of the effect of prolonged alcohol binge-like consumption and/or the effect of chronic tandospirone treatment on the density of BrdU and DCX immunoreactive cells in the dentate gyrus are shown (Fig. 3E, F, respectively).

To further assess whether the neuronal differentiation process was impaired by alcohol or tandospirone during the last 2 weeks of DID, we investigated the distribution of proliferation and immature neuron markers within the BrdU$^+$ cell population. We quantified the density of BrdU$^+$ cells co-expressing Ki67$^+$ (BrdU$^+$/Ki67$^+$: proliferating progenitors) or both Ki67 and DCX (BrdU$^+$/Ki67$^+$/DCX$^+$: differentiated neuroblast) (Fig. 4A). Quantification of the density of BrdU$^+$/Ki67$^+$ cells revealed no effect of alcohol exposure or tandospirone treatment compared to naive animals (Fig. 4B). However, alcohol exposure significantly reduces the density of BrdU$^+$/Ki67$^+$/DCX$^+$ cells compared to naive animals. Chronic treatment with tandospirone reversed this reduction (Fig. 4C). Furthermore, analysis of the distribution of the different cell population markers within BrdU$^+$ cells showed that long-term alcohol exposure alters the neuronal fate specification compared to naive animals, and chronic tandospirone treatment in alcohol-exposed animals restored a normal neurogenesis process (Fig. 4D). These results demonstrate that chronic partial activation of 5-HT$_{1A}$ receptors by 2-week tandospirone treatment is sufficient to totally reverse the neurogenetic and neuronal differentiation impairments elicited by 15-weeks of binge-like consumption in the DID.

**Discussion**

The present findings identify the importance of 5-HT$_{1A}$ receptors in alcohol withdrawal-induced anxiety, anxiety-driven alcohol drinking and alcohol-induced neurogenic deficits following long-term chronic binge-like voluntary consumption in the DID paradigm. Previous studies using forced alcohol administration, including liquid diet, gavage or vapors, have suggested the involvement of 5-HT$_{1A}$ in anxiety$^{36–38}$ and stress-induced anxiety$^{39}$ following acute or protracted withdrawal from chronic alcohol exposure. However, these studies have only suggested the contribution of 5-HT$_{1A}$ receptors using the partial-agonist buspirone, a non-selective drug that has been later shown to possess an antagonist activity at dopamine D2 receptors$^{40}$, which could explain the conflicting results showing sedative, anxiolytic, anxiogenic or ineffective properties of buspirone in various behavioral paradigms$^{36,38}$. Similarly, clinical testing of buspirone for the treatment of alcohol abuse or the management of withdrawal-induced anxiety has led to conflicting results$^{41,42}$, therefore raising uncertainty towards the efficacy of partial activation of 5-HT$_{1A}$ receptors in the treatment of alcohol use disorders.

The anxiolytic drug tandospirone is a 5-HT$_{1A}$ receptor partial agonist (60% efficacy) having two to three orders of magnitude less potency for adrenergic, muscarinic, dopamine or any other 5-HT receptors$^{43}$. Tandospirone’s binding sites are predominantly located in the hippocampus (dentate gyrus), lateral septum, entorhinal cortex, interpeduncular nucleus and dorsal raphe (DR) nucleus$^{44}$. The anxiolytic action of tandospirone in rodents has been observed in conflict$^{45}$, fear-conditioned freezing$^{46}$ and marble burying tests$^{47}$, yet a recent report failed to observe an anxiolytic action of tandospirone (3, 10 and 30 mg/kg) on rat basal anxiety in the elevated-plus-maze$^{48}$. Here, we have established the efficacy of tandospirone (3 mg/kg) to alleviate alcohol withdrawal-induced anxiety not only in marble burying and open-field tests, but also in the elevated-plus-maze. Whether the difference
between the aforementioned study and our work is related to the administration route (oral vs intraperitoneal in our study) or reveals a specific effect of tandospirone on alcohol withdrawal-induced-anxiety following long-term DID still needs to be determined.

Figure 2. Tandospirone reduces the maintenance of long-term binge-like alcohol consumption. (A) Experimental design of the testing of tandospirone on alcohol intake following 12 week of alcohol binge-like consumption in DID. (B, C) Tandospirone pre-treatment (Veh, 0.3, 1 and 3 mg/kg) reduces 30-min (B) and 2-h (C) ethanol intake (n = 11 mice). (D) Tandospirone pre-treatment (Veh, 0.3, 1 and 3 mg/kg) has no effect on 30-min sucrose intake (n = 10 mice). Data are presented as mean intake (g/kg) ± S.E.M. ****p < 0.0001; NS: non-significant (One-way ANOVA with repeated measures followed by Bonferroni post-hoc analysis). (E) Tandospirone reduces the locomotor activity immediately after injection but has no effect on locomotion during the behavioural or intake testing period. Data are presented as mean distance travelled per 5 min ± S.E.M; n = 6 mice/group. *p < 0.05; **p < 0.01 for the 3 mg/kg dose compared to vehicle (Two-way ANOVA followed by Bonferroni post-hoc analysis). (F–G) Tandospirone has no effect on the latency to (F) or the duration of (G) the Loss-Of-Righting-Reflex (LORR) induced by a sedative dose of ethanol. Data are presented as mean ± S.E.M; n = 6 mice/group (Unpaired two-tailed Student t-test).
Figure 3. Tandospirone reverses the alcohol-induced deficits in hippocampal neurogenesis. (A) Experimental design of chronic tandospirone and BrdU injections. After 12 weeks of DID, alcohol-exposed (EtOH) and naive (Naive) mice received a first BrdU injection (150 mg/kg, i.p.). Naive mice were then chronically treated with vehicle (Naive + Veh) and alcohol-exposed mice were chronically treated with either vehicle (EtOH + Veh) or Tandospirone (3 mg/kg/day) (EtOH + Tando), for 2 weeks. Mice were injected with BrdU (150 mg/kg, i.p.) at the end of each treatment week. Experiment ended after an extra week of DID and neurogenesis was assessed in n = 5 animals/group; 6 dentate gyri/animal. (B) Long-term chronic alcohol binge-like drinking in the DID reduces the density of BrdU-immunoreactive (BrdU+) cells in the dentate gyrus of the dorsal hippocampus and this effect was totally prevented by a two-week chronic treatment with tandospirone, as compared to ethanol naive mice treated with vehicle. (C) The density of Ki67-immunoreactive cells (Ki67+) is not affected by alcohol consumption or tandospirone treatment. (D) Long-term chronic alcohol binge-like drinking decreases the density of DCX-immunoreactive (DCX+) immature neurons in the dentate gyrus, and this reduction was prevented by a chronic tandospirone treatment, as compared to ethanol naive mice treated with vehicle. Data are presented as mean density of cells per mm² of granular layer ± S.E.M; n = 6 mice/group, 5 dentate gyri/mouse. **p < 0.01; ****p < 0.0001, NS: non-significant (One-way ANOVA followed by Bonferroni post-hoc analysis). (E,F) Left, middle and right vertical panels correspond to Naive + Veh, EtOH + Veh and EtOH + Tando, respectively. (E) Representative micrographs of the effect of long-term ethanol consumption and chronic tandospirone treatment on the density of BrdU+ cells in the sub-granular/granular layer of the dentate gyrus. Top horizontal panel shows lower magnification images, scale bar = 50 μm. Bottom horizontal panel shows higher magnification images, scale bar = 20 μm. Blue: DAPI, purple: BrdU, white arrowhead: BrdU+ cells. (F) Representative micrographs of the effect of long-term ethanol consumption and chronic tandospirone treatment on the density of DCX+ immature neurons in the sub-granular/granular layer of the dentate gyrus. Top horizontal panel shows lower magnification images, scale bar = 100 μm. Bottom horizontal panel shows higher magnification images, scale bar = 10 μm. Blue: DAPI, green: DCX, white asterisk: DCX+ immature neurons.
Figure 4. Tandospirone rescues alcohol-induced alterations in neuronal differentiation in the hippocampus. (A) Proliferation and neuronal fate specification/differentiation of BrdU+ cells (red) coexpressing DCX (green) and Ki67 (purple) and counterstained with DAPI (white). The left panel shows a BrdU+ cell only co-expressing Ki67 and the right panel a BrdU+ cell co-expressing both Ki67 and DCX. The bottom drawing illustrates the neuronal fate specification from BrdU/Ki67+ proliferating (non-differentiated) progenitors to BrdU/Ki67/DCX+ differentiated neuroblasts. (B) The density of BrdU/Ki67+ proliferating progenitors is not affected by alcohol consumption or tandospirone treatment. (C) Long-term chronic alcohol binge-like drinking decreases the density of BrdU/Ki67/DCX+ differentiated neuroblasts in the dentate gyrus, and this effect was totally abolished by chronic tandospirone treatment. Data are presented as mean density of cells per mm³ of granular layer ± S.E.M; n = 6 mice/group, 5 dentate gyri/mouse. *p < 0.05 (One-way ANOVA followed by Bonferroni post-hoc analysis). (D) Long-term alcohol binge-like consumption increases the proportion of BrdU progenitors that are proliferating, but reduces the neuronal differentiation of these progenitors. A chronic treatment with tandospirone totally restores a normal neuronal differentiation process in long-term ethanol-exposed mice, compared to ethanol naive mice treated with vehicle. Data are presented as mean percentage of BrdU+ cells ± S.E.M. **p < 0.01; ***p < 0.001, compared to proliferative progenitors (Two-way ANOVA with Bonferroni post-hoc test); ##p < 0.01 (χ² analysis of the distribution of the BrdU+ cells within proliferation and differentiation stages).
Chronic alcohol exposure increases the net excitation of dorsal raphe neurons and upregulates 5-HT1A autoreceptor expression, which has been postulated to contribute to anxiety during alcohol withdrawal. Conversely, tandospirone decreases the firing rate of DR 5-HT neurons and desensitizes 5-HT1A autoreceptors without affecting hippocampal 5-HT1A heteroreceptors. Hence, the observed effects of tandospirone may be mediated by its action on 5-HT1A autoreceptors, normalizing 5-HT neurotransmission in the DR and reducing both withdrawal-induced anxiety and the maintenance of alcohol binge-like drinking behavior in mice consuming alcohol from early adolescence through late adulthood. However, the anti-conflict effect of tandospirone is likely mediated by 5-HT1A receptors located in the dorsal hippocampus. Although 5-HT1A autoreceptors have been demonstrated to be developmentally necessary for the establishment of normal anxiety-like behavior, there is compelling evidence to suggest that 5-HT1A receptor agonists exert their anxiolytic effects postsynaptically in the hippocampus. Therefore, further work using local injections in the dorsal raphe or the hippocampus is needed to determine whether the anxiolytic effect of tandospirone in alcohol-withdrawn mice is mediated by 5-HT1A auto- or heteroreceptors. Alternatively, the development of biased 5-HT1A receptor partial agonists displaying high selectivity for either auto or heteroreceptors represents a potential strategy to resolve this question.

Raphe-hippocampal circuitry is complex, with the dorsal and ventral hippocampus differentially innervated by the dorsal as well as median raphe, with collateral interconnections within the ventral/dorsal hippocampus and the dorsal/median raphe. In addition, the neuronal activity of these regions is governed by cortico-hippocampal loops, forming a complex neural network that encodes the different aspect of reward processing. As a result, the role of the hippocampus in reward processing appears to be topographically organized, with the dorsal hippocampus likely playing a more prominent role in contextual/spatial memory and the ventral hippocampus more involved in emotional/motivation-related memory. Thus, tandospirone might act presynaptically on 5-HT1A autoreceptors as a full agonist in the dorsal and as a partial agonist in the median raphe to differentially inhibit 5-HT release in target brain regions, including the ventral/dorsal hippocampus, as well as the prefrontal cortex, the amygdala or the bed nucleus of the stria terminalis, brain regions in which serotonin signaling has been widely implicated in both alcohol drinking behaviors and withdrawal-associated emotional deficits. Tandospirone could also act postsynaptically as a full agonist on 5-HT1A heteroreceptors located in different neuronal subtypes (glutamate versus GABA neurons) in those brain regions to modulate their excitability/activity. Further work using recent advances in optogenetics and/or chemogenetics would help to dissect the region- and circuit-specific contribution of 5-HT1A auto- and heteroreceptors in alcohol drinking behavior and associated emotional or neurogenic deficits.

Over previous decades, a large body of preclinical and clinical evidence has linked 5-HT homeostasis deficits to hippocampal neurogenesis impairments and depression-related disorders. More recently, adult hippocampal neurogenesis has also been reported to modulate anxiety-like behavior in rodents. Repeated cycles of binge-like alcohol exposure for relatively short periods of time (4 days to 7 weeks), using forced-consumption (intra-gastric gavage or ethanol vapors), alcohol-containing diet or sweetened-solution fading procedures, produces anxiety-like behavior concomitant to reduced progenitor proliferation (BrdU incorporation and Ki67 labeling) and impaired neuronal differentiation (DCX labeling) in the dentate gyrus. Similarly, 12 days of voluntary binge-like consumption of sweetened ethanol was shown to produce anxiety- and depression-like behavior, and reduce the density of BrdU+ proliferating cells and DCX+ immature neurons. Here, we showed that long-term voluntary binge-like consumption of ethanol in the DID, from early adolescence through late adulthood, not only leads to significant reductions in progenitor proliferation in the DG but, once they have proliferated, their neuronal fate specification is altered. Interestingly, we were able to reverse both proliferation and differentiation deficits with a chronic tandospirone treatment for the last two weeks of a 15-week exposure in the DID. It suggests that impairments in neurogenesis following long-term binge-like voluntary consumption of alcohol might be mediated, at least in part, by a 5-HT1A receptor-dependent mechanism. One explanation could be that chronic alcohol exposure might reduce the expression and/or function of 5-HT1A heteroreceptors within the dentate gyrus, as previously described. This reduction in 5-HT1A receptors expression or function could result from a reduction in BDNF/TrkB signaling induced by chronic alcohol exposure. In turn, decreased 5-HT1A function might alter CREB phosphorylation pathway activation, which could lead to decreased neurogenesis, and increased anxiety-like behavior. On the other hand, an upregulation of 5-HT1A autoreceptors might contribute to the effect seen on alcohol drinking and anxiety-related behavior. Hence, tandospirone might act as a partial agonist on 5-HT1A autoreceptors and a full agonist on 5-HT1A heteroreceptors, to compensate for altered 5-HT1A receptor signaling in the dorsal raphe and the hippocampus, reduce anxiety-like behavior and correct the neurogenic deficits, respectively. Since similar alterations in hippocampal neurogenesis have been observed following chronic binge-like alcohol administration by gastric gavage in rats, with these changes associated with concomitant cognitive impairments, further work is required to determine whether neurogenic deficits following long-term DID lead to cognitive deficits and whether these deficits are mediated by a 5-HT1A receptor-dependent mechanism.

Methods
Animals and housing. Five-week-old male C57BL/6J mice (ARC, WA, Australia) were individually housed under reverse light cycle conditions (lights off at 9:00 am) in a climate-controlled room with ad libitum access to food and water. Following 1 week of habituation to the housing conditions, mice were offered alcohol during the drinking sessions. All experimental procedures were approved by The University of Queensland and The Queensland University of Technology Animal Ethics Committees and complied with the policies and regulations regarding animal experimentation and other ethical matters, in accordance with the Queensland Government Animal Research Act 2001, associated Animal Care and Protection Regulations (2002 and 2008), as well as the Australian Code for the Care and Use of Animals for Scientific Purposes, 8th Edition (National Health and Medical Research Council, 2013).
Drugs and Chemicals. Tandospirone (Sigma-Aldrich, NSW, Australia) was dissolved in 2% dimethyl sulfoxide (DMSO) and saline (0.9% NaCl). The 20% alcohol (v/v) solution was prepared using 100% food grade ethyl alcohol (Recochem, SA, Australia) and filtered water. The 5% sucrose (w/v) (Chem supply, SA, Australia) solution was prepared in filtered water. BrdU (5-Bromo-2′-deoxyuridine, Sigma-Aldrich) was dissolved in 1% DMSO and 0.1 M phosphate buffered saline (PBS, pH 7.4).

Drinking-In-the-Dark (DID) paradigm. We adapted the Drinking-In-the-Dark (DID) model of binge-like alcohol8 or sucrose consumption with long-term exposure as previously described29,66. Mice were given access to one bottle of 20% (v/v) alcohol for a 2 h period (12 pm to 2 pm), 3 h into the dark cycle, Monday to Friday. Filtered water was available at all other times. The alcohol solution was presented in 50 ml plastic falcon tubes (Corning Centristar, NY, USA) fitted with rubber stoppers and a 6.35 cm stainless-steel sipper tube with double ball bearings. Alcohol containing tubes were weighed prior to and 30 min and 2 h after presentation. Mouse weights were measured daily to calculate the adjusted g/kg intake. We also measured binge-like long-term sucrose consumption by adapting the DID paradigm: mice were given access to one bottle of 5% (w/v) sucrose instead of alcohol.

Acute tandospirone testing. Following 12 weeks of DID, mice consuming stable baseline levels of 20% alcohol (Figure S1c) were divided in two groups for the testing of acute tandospirone on (1) anxiety or (2) the maintenance of alcohol and sucrose drinking, 24 h after the last drinking session.

• For the anxiety-related behavioral experiments, tandospirone (vehicle or 3 mg/kg) was intraperitoneally (i.p.) administrated 30 min prior to behavioral testing. Each of the 3 tests was conducted 1 week apart, over 3 weeks. In all the tests, alcohol-withdrawn mice were assigned to one of two treatment groups: vehicle (AW + Veh) or tandospirone 3 mg/kg (AW + Tando) and the alcohol naïve age-matched mice were assigned to the vehicle group (Naive + Veh), n = 5–6 animals/group.

• For the experiments on the maintenance of alcohol or sucrose drinking, tandospirone (vehicle, 0.3, 1, 3 mg/kg) was intraperitoneally (i.p.) administrated to mice consuming stable levels of 20% ethanol (n = 11) or 5% sucrose (n = 10). The drug testing was carried out seven days apart, using a Latin square design, thus each animal randomly received one of the 4 doses each week. After 4 weeks, each animal had received all the 4 doses and serves as its own control. Tandospirone was administrated 30 min before the presentation of the bottles.

Anxiety-related behavior. For the testing of withdrawal-induced anxiety-like behavior, experiments were carried out 24 h after the last drinking session of the week. Marble burying was performed in novel individual plastic cages (21 × 38 × 14 cm) containing 5-cm thick sawdust bedding. Ten glass marbles (diameter 10–12 mm) were arranged on the bedding evenly spaced in 2 rows of 5 marbles. After 20 min, the number of unburred marbles was averaged from counting by two experimenters blind to the treatments. A marble covered at least two-third (2/3) of its size by saw dust was considered as “buried”. Elevated-plus-maze was carried out in an apparatus consisting of four arms (35 cm × 5 cm), elevated 50 cm above the floor. The closed arms were enclosed with 40 cm high walls. The experiment was conducted for 5 min, with initial mouse placement in the center, facing the open arm67. The number of entries and time spent in each arm was recorded using ANY-maze tracking software. A marble covered at least two-thirds (2/3) of its size by saw dust was considered as “buried”.

General locomotor activity. Locomotor activity was performed as previously described29,66. The study was run in 4 daily 2 h sessions. After habituation (day 1–3), testing was conducted on day 4. Alcohol naïve mice (13–15 week-old) were assigned to one of three treatment groups: vehicle or tandospirone (1 or 3 mg/kg), n = 6 animals per group. After 60 min, animals were i.p. injected with the assigned treatment and the locomotor activity was recorded for 60 min using ANY-Maze tracking software. Data was collected across the entire 2 h session and recorded as distance travelled in meters per 5 min.

Loss of Righting Reflex (LORR). LORR experiment was performed as previously described29,66. A sedative dose of 3.2 g/kg (20% v/v, i.p.) of ethanol was administered to test the effects of tandospirone on alcohol metabolism. Ethanol naïve mice were divided into two groups that either received saline or tandospirone (3 mg/kg, i.p.), 30 min before ethanol was administered. The latency to LORR was recorded as the time from ethanol injection to the time the mouse was unable to right itself 3 times within a 15-second period from the supine position. Duration of LORR was recorded as the time elapsed until it recovered and was able to right itself 3 times within a 15-second period.

Chronic tandospirone testing on neurogenesis. Following 12 weeks of alcohol drinking in the DID, Tandospirone 3 mg/kg/day was i.p. injected immediately after each drinking session to prevent any effect on alcohol consumption levels (Figure S1d) for 2 weeks. A total of three injections of BrdU (150 mg/kg, i.p.) were performed over the 2 week treatment (days 0, 7 and 15). This non-toxic dose has been reported to label all actively dividing precursors in the mouse subgranular zone68. Twenty-four hours after the last BrdU injection, animals were transcardially perfused with 4% paraformaldehyde. Brains were harvested and postfixed overnight at 4 °C, incubated in sucrose 20–30%, embedded in Optimal Cutting Temperature (OCT, Tissue-Tek) medium, and kept at −80 °C until histology and immunohistochemistry processing. Twenty micron-thick coronal cryostat sections...
were collected and kept floating in ice-cold PBS. After 3 thorough washes in PBS, slices were immersed in ice-cold 10% methanol-PBS solution for 5 min. After 3 washes in citrate buffer solution (10 mM citrate buffer, 0.05% Tween 20, pH 6.0) at room temperature, sections were incubated in a 37 °C pre-heated citrate buffer solution and placed at 95 °C for 20 min, rinsed 3 times in PBS and incubated overnight in blocking solution (4% normal goat serum–NGS, 1% bovine serum albumin–BSA, 0.3% Triton X100 and 0.05% Tween 20). Sections containing the dorsal hippocampus (Bregma –1.5 mm to –2 mm) were incubated overnight at 4 °C with primary antibodies: rabbit anti-DCX (Abcam #18723, 1:500); mouse anti-Ki67 (BD bioscience #550609, 1:20) and rat anti-BrdU (Abcam #6326, 1:200) and with corresponding secondary antibodies, for 2 h at room temperature: goat anti-rabbit–Alexa488; goat anti-mouse–CY5; goat anti-rat–Biotin (Thermofisher Scientific, 1:500) and 30 min at room temperature with Streptavidin–Cy3 (Thermofisher Scientific, 1:1000). Sections were mounted in Prolong gold antifade mountant with DAPI (Thermofisher Scientific).

Imaging and Analysis. Whole dentate gyri of 3 coronal sections per animals (n = 5–6 animals/group) were imaged on a Nikon/Spectral Spinning Disk confocal microscope in mosaics using a 40× oil-immersion objective (NA 1.35), with a z-step of 0.5 μm. Four-channel mosaic images (.nd2) were deconvolved using Huygens professional v16.10 (Scientific Volume Imaging, The Netherlands) with iteration number set at 100, quality threshold at 0.001, signal to noise ratio at 15 for the 4 channels and converted in .tif for subsequent quantification in professional v16.10 (Scientific Volume Imaging, The Netherlands) with iteration number set at 100, quality threshold set at 0.001, signal-to-noise ratio at 15 for the 4 channels and converted in .tif for subsequent quantification in Icy (Icy, v1.8.0, DFKI, Germany). A 3D rendering of the images was performed by an experimenter blind to the treatment, averaged per animal and plot as mean ± SEM for each group. Density of counted cells was normalized to the volume of granular cell layer sampled in each group. Representative images were taken on a Olympus FV1200 confocal microscope using a 60× oil-objective (NA 1.35), x3.0 numerical zoom and 0.5 z-step.

Statistics. GraphPad Prism 7 (Graph Pad Software Co., CA, USA) was used for all statistical analysis. Comparisons between groups were statistically analysed using t-test, one-way or two-way ANOVA followed by a Bonferroni multi comparisons post-hoc test. A p value < 0.05 was considered significant. All values are expressed as the mean ± SEM. Distribution of the different markers within BrdU-immunoreactive cell population was compared between groups using the Chi-squared (χ²) test. A p value < 0.05 was considered significant. Detailed statistical analysis is provided in Table S1.

References
1. Koob, G. F. In Handbook of Clinical Neurology (ed. Pfefferbaum, E. V. S. and A.) 125, 33–54 (Elsevier, 2014).
2. Lynskey, M. T. The comorbidity of alcohol dependence and affective disorders: treatment implications. Drug Alcohol Depend. 52, 201–209 (1998).
3. Breese, G. R. et al. Stress enhancement of craving during sobriety: a risk for relapse. Alcohol. Clin. Exp. Res. 29, 185–195 (2005).
4. Becker, H. C. Effects of alcohol dependence and withdrawal on stress responsiveness and alcohol consumption. Alcohol Res. Curr. Rev. 34, 448–458 (2012).
5. Kliethermes, C. L. et al. Anxiety-like behavior in mice in two apparatuses during withdrawal from chronic ethanol vapor inhalation. Alcohol. Clin. Exp. Res. 28, 1012–1019 (2004).
6. Stevenson, J. R. et al. Abstinence following alcohol drinking produces depression-like behavior and reduced hippocampal neurogenesis in mice. Neuropsychopharmacology 34, 1209–1222 (2009).
7. Nixon, K. & Crews, F. T. Binge ethanol exposure decreases neurogenesis in adult rat hippocampus. J. Neurochem. 83, 1087–1093 (2002).
8. Rhodes, J. S. et al. Evaluation of a simple model of ethanol drinking to intoxication in C57BL/6j mice. Physiol. Behav. 84, 53–63 (2005).
9. Lee, K. M. et al. Binge Alcohol Drinking Elicits Persistent Negative Affect in Mice. Behav. Brain Res. https://doi.org/10.1016/j.bbr.2015.05.055 (2015).
10. Belmer, A. et al. Serotonergic Neuroplasticity in Alcohol Addiction. Brain Plast. 1, 177–206 (2016).
11. Santarelli, L. et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805–809 (2003).
12. Richardson-Jones, J. W. et al. Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety. J. Neurosci. Off. J. Soc. Neurosci. 31, 6008–6018 (2011).
13. Popa, D. et al. A longitudinal study of 5-HT outflow during chronic fluoxetine treatment using a new technique of chronic microdialysis in a highly emotional mouse strain. Eur. J. Pharmacol. 628, 83–90 (2010).
14. Zhang, J. et al. CREB-mediated synaptogenesis and neurogenesis is crucial for the role of 5-HT1A receptors in modulating anxiety behaviors. Sci. Rep. 6, 29551 (2016).
15. Kelai, S. et al. Chronic voluntary ethanol intake hypersensitizes 5-HT1A autoreceptors in C57BL/6j mice. J. Neurochem. 107, 1660–1670 (2008).
16. Nevo, I. et al. Chronic alcoholization alters the expression of 5-HT1A and 5-HT1B receptor subtypes in rat brain. Eur. J. Pharmacol. 281, 229–239 (1995).
17. Hedlund, L. & Wåhlström, G. Buspirone as an Inhibitor of Voluntary Ethanol Intake in Male Rats. Alcohol Alcohol 31, 149–156 (1996).
18. Breese, G. R. et al. Prior Multiple Ethanol Withdrawals Enhance Stress-Induced Anxiety-Like Behavior: Inhibition by CRF1- and Benzodiazepine-Receptor Antagonists and a 5-HT1a-Receptor Agonist. Neuropsychopharmacology 30, 1662–1669 (2005).
19. Overstreet, D. H. et al. A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats. Psychopharmacology (Berl.) 167, 344–352 (2003).
20. Lal, H. et al. Anxiogenic behavior in rats during acute and protracted ethanol withdrawal: reversal by buspirone. Alcohol Fayettev. N 8, 467–471 (1991).
21. Roof, R. A. et al. Buspirone is a potent antagonist at D3 and D4 Dopamine Receptors and attenuates the reinforcing effects of cocaine in a primate model. FASEB J. 26, 661.4–661.4 (2012).
22. Leggio, G. M. et al. Dopamine D3 Receptor Is Necessary for Ethanol Consumption: An Approach with Buspirone. Neuropsychopharmacology 39, 2017–2028 (2014).
23. Pich, E. M. & Samanin, R. Disinhibitory effects of buspirone and low doses of sulpiride and haloperidol in two experimental anxiety models in rats: possible role of dopamine. Psychopharmacology (Berl.) 89, 125–130 (1986).
24. Kitamura, Y. & Nagatani, T. Buspirone enhances immobility in the forced swim test in mice. Pharmacol. Biochem. Behav. 55, 445–451 (1996).
25. Cao, B. I. & Rodgers, R. J. Comparative behavioural profiles of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in the murine elevated plus-maze. Neuropharmacology 36, 1089–1097 (1997).
26. Collinson, N. & Dawson, G. R. On the elevated plus-maze the anxiolytic-like effects of the 5-HT1A agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT1A partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635. Psychopharmacology (Berl.) 132, 35–43 (1997).
27. Kumar, J. R. et al. Nucleus incertus contributes to an anxiogenic effect of buspirone in rats: Involvement of 5-HT1A receptors. Neuropharmacology 110, 1–14 (2016).
28. Lim, L. W. et al. Effect of buspirone on the behavioral regulation of rats in low versus high anxiety conditions. Arzneimittelforschung. 58, 269–276 (2008).
29. Patkar, O. L. et al. The antihypertensive drug pindolol attenuates long-term but not short-term binge-like ethanol consumption in mice. Addict. Biol. https://doi.org/10.1111/adb.12339 (2016). In press.
30. Rodgers, R. J. et al. Behavioural effects in mice of subchronic buspirone, ondansetron and tianeptine. II. The elevated plus-maze. Pharmacol. Biochem. Behav. 56, 295–303 (1997).
31. Malec, E. J. et al. Efficacy of Buspirone in Alcohol Dependence: A Review. Alcohol. Clin. Exp. Res. 20, 853–858 (1996).
32. Hamik, A. et al. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol. Psychiatry 28, 99–109 (1990).
33. Evans, S. M. et al. Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans. J. Pharmacol. Exp. Ther. 271, 683–694 (1994).
34. Mori, M. et al. Chronic Treatment with the 5-HT1A Receptor Partial Agonist Tandospirone Increases Hippocampal Neurogenesis. Neurrol. Ther. 3, 67–77 (2014).
35. Murata, Y. et al. Chronic treatment with tandospirone, a serotonin 1A receptor partial agonist, inhibits psychosocial stress-induced changes in hippocampal neurogenesis and behavior. J. Affect. Disord. 180, 1–9 (2015).
36. Overstreet, D. H. et al. Reduction in repeated ethanol-withdrawal-induced anxiety-like behavior by site-selective injections of 5-HT1A and 5-HT2C ligands. Psychopharmacology (Berl.) 187, 1–12 (2006).
37. Wills, T. A. et al. Sensitization, duration, and pharmacological blockade of anxiety-like behavior following repeated ethanol withdrawal in adolescent and adult rats. Alcohol. Clin. Exp. Res. 33, 455–463 (2009).
38. Lowery-Gianta, E. G. et al. Functional Alterations in the Dorsal Raphe Nucleus Following Acute and Chronic Ethanol Exposure. Neuropsychopharmacology. https://doi.org/10.1038/npp.2014.205 (2014).
39. Breese, G. R. et al. Stress sensitization of ethanol withdrawal-induced reduction in social interaction: inhibition by CRF-1 and benzodiazepine receptor antagonists and a 5-HT1A-receptor agonist. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 29, 470–482 (2004).
40. Jadhav, S. A. et al. Dose-dependent response of central dopaminergic systems to buspirone in mice. Indian J. Exp. Biol. 46, 704–714 (2008).
41. Pokk, P. & Zharkovsky, A. The effects of buspirone on the behaviour of control and stressed mice. J. Physiol. Pharmacol. Off. J. Pol. Physiol. Soc. 49, 175–185 (1998).
42. Malec, E. J. et al. Buspirone in the treatment of alcohol dependence: a placebo-controlled trial. Alcohol. Clin. Exp. Res. 20, 307–312 (1996).
43. Dougherty, R. J. & Gates, R. R. The role of buspirone in the management of alcohol withdrawal: a preliminary investigation. J. Subst. Abuse Treat. 7, 189–192 (1990).
44. Tanaka, H. et al. Autoradiographic localization and pharmacological characterization of [3H]tandospirone binding sites in the rat brain. Brain Res. 546, 181–189 (1991).
45. Kataoka, Y. et al. Involvement of the dorsal hippocampus in mediation of the antianxiety action of tandospirone, a 5-hydroxytryptamine1A agonistic anxiolytic. Neuropharmacology 30, 475–480 (1991).
46. Nishitsuji, K. et al. The pharmacokinetics and pharmacodynamics of tandospirone in rats exposed to conditioned fear stress. Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. 16, 376–382 (2006).
47. Abe, M. et al. Effect of 5-[[125I]-1,4-benzodioxan-2-ylmethyl]amino[propoxy]–1,3-benzodioxole HCl (MKC-242), a novel 5-HT1A-receptor agonist, on aggressive behavior and marble burying behavior in mice. Jpn. J. Pharmacol. 76, 297–304 (1998).
48. Kasahara, K. et al. The effects of AP521, a novel anxiolytic drug, in three anxiety models and on serotonergic neural transmission in rats. J. Pharmacol. Sci. 127, 109–116 (2015).
49. Godbout, R. et al. Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine—I. Effects of acute and long-term administration of tandospirone on serotonin neurotransmission. Neuropharmacology 30, 679–690 (1991).
50. Prezgalinski, E. et al. Stimulation of post-synaptic 5-HT1A receptors is responsible for the anticonflict effect of ipsapirone in rats. J. Pharm. Pharmacol. 44, 780–782 (1992).
51. Stefiński, R. et al. Serotonergic innervation of the hippocampus and nucleus accumbens septi and the anxiolytic-like action of midazolam and 5-HT1A receptor agonists. Neuropharmacology 32, 977–985 (1993).
52. Carli, M. et al. Stimulation of hippocampal 5-HT1A receptors causes amnesia and anxiolytic-like but not antidepressant-like effects in the rat. Eur. J. Pharmacol. 234, 215–221 (1993).
53. Becker, G. et al. Selective serotonin 5-HT1A receptor biased agonists elicit distinct brain activation patterns: a pharmacomRI study. Sci. Rep. 6, 26633 (2016).
54. Möldner, D. I. et al. Serotonin neuronal release from dorsal hippocampus following electrical stimulation of the dorsal and median raphe nuclei in conscious rats. Hippocampus 8, 262–273 (1998).
55. Haber, S. N. & Knautson, B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 35, 4–26 (2010).
56. Pierard, C. et al. Different implications of the dorsal and ventral hippocampus on contextual memory retrieval after stress. Hippocampus 27, 999–1015 (2017).
57. Riaz, S. et al. Ventral, but not dorsal, hippocampus inactivation impairs reward memory expression and retrieval in contexts defined by proximal cues. Hippocampus 27, 822–836 (2017).
58. Celada, P. et al. Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research. CNS Drugs 27, 703–716 (2013).
59. Casanovas, J. M. & Artigas, F. Differential effects of ipsapirone on 5-hydroxytryptamine release in the dorsal and median raphe neuronal pathways. J. Neurochem. 67, 1945–1952 (1996).
60. Marczin, V. et al. Serotonergic Systems in the Pathophysiology of Alcohol Dependence: Relevance to Clinical Alcoholism. ACS Chem. Neurosci. 6, 1026–1039 (2015).
61. Revest, J.-M. et al. Adult hippocampal neurogenesis is involved in anxiety-related behaviors. Mol. Psychiatry 14, 959–967 (2009).
62. Gei, C. R. et al. Alcohol and adult hippocampal neurogenesis: promiscuous drug, wanton effects. Prog. Neuropsychopharmacol. Biol. Psychiatry 54, 103–113 (2014).
63. Briones, T. L. & Woods, J. Chronic binge-like alcohol consumption in adolescence causes depression-like symptoms possibly mediated by the effects of BDNF on neurogenesis. Neuroscience 254, 324–334 (2013).
64. Burke, T. F. et al. Sensitivity of hippocampal 5-HT1A receptors to mild stress in BDNF-deficient mice. Int. J. Neuropsychopharmacol. 16, 631–645 (2013).
65. Vetreno, R. P. & Crews, F. T. Binge ethanol exposure during adolescence leads to a persistent loss of neurogenesis in the dorsal and ventral hippocampus that is associated with impaired adult cognitive functioning. *Front. Neurosci.* **9**, 35 (2015).

66. Patkar, O. L. *et al.* The effect of varenicline on binge-like ethanol consumption in mice is β4 nicotinic acetylcholine receptor-independent. *Neurosci. Lett.* **633**, 235–239 (2016).

67. Walf, A. A. & Frye, C. A. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. *Nat. Protoc.* **2**, 322–328 (2007).

68. Mandyam, C. D. *et al.* Determination of key aspects of precursor cell proliferation, cell cycle length and kinetics in the adult mouse subgranular zone. *Neuroscience* **146**, 108–122 (2007).

**Acknowledgements**

This work was supported by funding from grants from the Australian Research Council (FT1110884) to S.E.B and the National Health and Medical Research Council (AP1061979) to S.E.B.

**Author Contributions**

A.B. and S.E.B. were responsible for the study concept and design. A.B. and O.L.P. carried out behavioural animal experiments. A.B. performed the immunohistochemistry experiments, O.L.P. acquired the images, and V.L. deconvolved the images. A.B. and O.P. analyzed the data and interpreted the findings. A.B. drafted the manuscript. S.E.B., O.L.P. and V.L. reviewed the manuscript. A.B. revised the manuscript. All authors have critically reviewed the content and approved final version for submission.

**Additional Information**

**Supplementary information** accompanies this paper at https://doi.org/10.1038/s41598-018-20504-z.

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018